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INTRODUCTION
Lung cancer is the main cause of cancer-related death world-
wide. In Korea, according to the statistics reported in 2005,
lung cancer is the second and fifth most common cancer in
men and women, respectively. Moreover, lung cancer is the
most common cancer in elderly men (≥65 age group) (1).
Non-small cell lung cancer (NSCLC) is found in >80% of
all cases; most patients present with advanced or metastatic
disease. These cases with advanced stages (IIIB or IV) can-
not be cured with current therapies. Thus, life prolongation
and symptom palliation are the main goals of treatment for
these patients. 
The standard first-line treatment for advanced NSCLC, in
patients with good performance status (PS), consists of plat-
inum-based combinations. This therapy has been shown to
provide a survival advantage over supportive care alone (2).
However, despite adequate first-line chemotherapy, the major-
ity of patients will experience disease progression. In the set-
ting of second-line treatment, docetaxel has demonstrated
superiority for 1-yr survival and quality of life compared with
ifosfamide, vinorelbine or supportive care alone (3, 4); at a
recommended dose of 75 mg/m2 every 3 weeks. 
Elderly patients or patients with poor PS have been histor-
ically excluded from large randomized clinical trials, and thus
limited evidence-based data are available to guide the treat-
ment of these patients. Single agent therapy remains a valid
option for elderly patients with NSCLC (5); a large Italian
study failed to demonstrate a benefit for combination thera-
py over single agent therapy (6). For patients with poor PS,
data are more scant and few randomized trials comparing sin-
gle-agent with combination chemotherapy have been report-
ed in this subgroup. The recent American Society of Clinical
Oncology (ASCO) guidelines recommended single agent
therapy for the treatment of elderly and PS 2 patients (7).
During the initial introduction of docetaxel, it was rou-
tinely administered once every 3 weeks. However, although
docetaxel was effective salvage treatment in patients previ-
ously treated with platinum-based chemotherapy, hemato-
logical toxicity was substantial with the 3-week treatment
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Although docetaxel monotherapy has shown clinical benefits for previously treated
patients with advanced non-small cell lung cancer (NSCLC), the efficacy of salvage
docetaxel chemotherapy for elderly patients or patients with poor performance sta-
tus (PS) is controversial. Therefore, we conducted a phase II trial to evaluate the
safety and efficacy of weekly low-dose docetaxel monotherapy in these patients.
Forty NSCLC patients, who had been previously treated with one or more chemother-
apy regimens, received docetaxel at a dose of 25 mg/m
2 weekly on days 1, 8, and
15 of a 28-day cycle. All patients were ≥ ≥65 yr or had a PS of grade 2 in the cases
of <65 yr. Weekly low-dose docetaxel was well-tolerated. Grade 3/4 non-hemato-
logic toxicities were rare; fatigue in 3 patients (8%), anorexia in 3 patients (8%) and
stomatitis in 2 patients (5%). Grade 3/4 neutropenia was noted in only one patient
(3%). By intent-to-treat analysis, nine patients (23%) had partial responses and
eleven patients (28%) demonstrated stable disease. The median progression-free
survival and overall survival were 9.9 weeks and 37.7 weeks, respectively. Weekly
low-dose docetaxel therapy provides a reasonable alternative for NSCLC salvage
treatment in pretreated elderly patients or in patients with a reduced PS.
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schedule; grade 3 or 4 neutropenia was observed in 54-67%
of patients treated with a 75 mg/m2 dose of docetaxel (3, 4,
8). Even at a 60 mg/m2 dose, grade 3 or 4 neutropenia devel-
oped in more than 80% of patients in a Japanese trial (9).
However, recent randomized clinical trials showed that doc-
etaxel on a weekly schedule has a similar efficacy as the 3-week-
ly regimen and has less severe neutropenia (10-13). Patients
with advanced age or poor PS are usually not candidates for
the 3-weekly full-dose docetaxel monotherapy due to the
severe toxicities. Therefore, treatment with weekly docetax-
el provides an attractive treatment option for elderly or less
fit patients with poor PS. 
Based on the efficacy of salvage docetaxel chemotherapy
in NSCLC and its relatively favorable toxicity profiles, when
used on a weekly schedule, we conducted this phase II trial
to test the safety and efficacy of weekly docetaxel monother-
apy in previously treated elderly or less fit patients with poor
PS. A weekly low-dose regimen of docetaxel (25 mg/m2/
week) was chosen, due to the fragility of the study popula-
tion. 
MATERIALS AND METHODS
Eligibility 
To be eligible for this study, patients were required to have:
histologically confirmed stage IIIB (malignant effusion) or
IV NSCLC that progressed after one or more prior chemother-
apeutic regimens. Patients who were ≥65 yr with an East-
ern Cooperative Oncology Group (ECOG) PS of grade ≤2
were enrolled. In the cases where the patients were <65 yr,
the ECOG PS should be grade 2. All patients were required
to have at least one measurable disease (defined as a mass
with demarcated dimensions by computed tomography [CT],
routine chest radiography or by physical examination). In
addition, adequate hematological counts were required (abso-
lute neutrophil count [ANC] ≥1.5×109/L and platelet
count ≥100×109/L) and laboratory results had to be with-
in the following limits (serum bilirubin ≤1.25×upper
normal limit [UNL], serum aspartate aminotransferase [AST]
and alanine aminotransferase [ALT] ≤1.5×UNL, serum
alkaline phosphatase ≤5.0×UNL, and serum creatinine
≤1.5 mg/dL). Patients treated for brain metastases by radi-
ation were eligible if they were neurologically stable. 
Patients were not eligible if they had a history of a prior
or a concomitant malignancy, except for cases with treated
non-melanoma skin cancer or in situ cervical cancer. Patients
with pre-existing sensory or motor neurological symptoms
of ≥grade 2 according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) were excluded as well
as patients with active infections or other serious underlying
medical conditions that might have impaired the ability of
the patient to receive the planned protocol of treatment. All
patients gave written informed consent before initiating
treatment according to institutional regulations. 
Pretreatment evaluation
Before initiation of the chemotherapy, the patients were
evaluated as follows: medical history, physical examination,
determination of ECOG PS, complete blood cell counts, bio-
chemical tests and tumor evaluation. A chest radiography
and chest CT scan (including liver and adrenal glands) were
required. A bone scan and brain imaging were performed
only if clinically indicated.
Treatment plan 
Docetaxel 25 mg/m2 was administered weekly intravenous-
ly (i.v.) as a 1-hr infusion on an outpatient basis. Docetaxel
was given for three consecutive weeks. This was followed by
a treatment-free week. These cycles were repeated every 4
weeks for a maximum of 6 cycles. The premedication was as
follows: one dose of 10 mg i.v. dexamethasone (30 min before
chemotherapy) and two doses of 8 mg oral dexamethasone
(12 hr and 24 hr after chemotherapy). All patients received
adequate antiemetic therapy prior to the chemotherapy. Gran-
ulocyte colony-stimulating factor (G-CSF) was not routine-
ly administered. 
Dose modifications based on hematological toxicity were
made as follows: at the start of each cycle, the ANC was
required to be ≥1,500/μ L and the platelet count ≥75,000/
μ L. If the ANC was <1,500/μ L or the platelet count was
<75,000/μ L, the treatment was withheld that week, and
the blood counts were reevaluated the following week. The
treatment proceeded as scheduled if the blood cell count
increased to an ANC ≥1,500/μ L and a platelet count ≥
75,000/μ L. A 25% dose reduction was required if patients
developed a grade 4 neutropenia, febrile neutropenia or a
grade 4 thrombocytopenia. Dose adjustments were also made
for patients with non-hematological toxicities. When a non-
hematological toxicity of grade ≥3 developed, with the excep-
tion of alopecia or emesis, the dose of docetaxel was held
until the toxicity resolved to less than grade 2, and then the
docetaxel was given at 75% of the initial dose. If the non-
hematological toxicity was grade 2, the dose of docetaxel was
held until the toxicity resolved to a grade ≤1 and then the
docetaxel was given at a dose of 25 mg/m2. The missed doses
were not made up. Patients were withdrawn from the study
when the delay of treatment was greater than one cycle, i.e.
4 weeks. The chemotherapy was discontinued for patients
with progressive disease (PD) or unacceptable toxicity.
Response to treatment and adverse effects
Physical examination, complete blood counts and biochem-
ical tests were carried out before each cycle of therapy. Tumors994 K.-W. Lee, J.H. Lim, J.H. Kim, et al.
were measured every 2 cycles (8 weeks) by imaging studies
using the same procedures described for the pretreatment
evaluation. The responses were assessed using the Response
Evaluation Criteria in Solid Tumors (RECIST). A complete
response (CR) was defined as the disappearance of all clini-
cal evidence of tumor. A partial response (PR) was defined
as a sustained ≥30% decrease in the sum of the longest
diameter (LD) of target lesions, taking as reference the base-
line sum LD. Confirmatory CT scans after 4 weeks in patients
with CR or PR were not performed if patients’ symptoms,
physical examination or chest-x ray before the next chemother-
apy cycle did not have the evidence of disease progression.
PD was defined as at least a 20% increase in the sum of the
LD of target lesions, taking as reference the smallest sum
LD recorded since the treatment started or the appearance of
new lesions. Stable disease (SD) was defined as a tumor response
that did not meet the above CR, PR or PD criteria. Toxici-
ties were evaluated using the NCI-CTC (version 3.0) before
each treatment. 
Statistical analysis 
The primary study endpoint was the response rate to weekly
low-dose docetaxel treatment. Progression-free survival (PFS)
and overall survival (OS) were secondary endpoints. The PFS
was calculated from the first day of chemotherapy to the date
of disease progression, death from any cause or to the date of
the last follow-up if none of the preceding events had occurred.
OS was calculated from the first day of chemotherapy to the
date of death or the last follow-up visit. Analyses of PFS and
OS curves were performed using the Kaplan-Meier method. 
This trial was designed to detect a response rate of 20%
compared to a minimal, clinically meaningful response rate
of 5%. An optimal Simon two-step design was used (14),
with a power of 90% to accept the hypothesis and a 10%
significance to reject the hypothesis. Twelve patients were
initially recruited, with the intention that if no response was
observed, the trial would have been discontinued. However,
the trial would continue and 37 patients would be recruited
to evaluate the response to weekly docetaxel chemotherapy,
if at least one of the 12 patients showed an objective response. 
RESULTS
Patient characteristics
From May 2004 to January 2007, 40 patients were enrolled
at Seoul National University Bundang Hospital. The patient
characteristics are shown in Table 1. There were 24 males
and 16 females with a median age of 66 yr (range: 33-80
yr). Thirty patients (75%) had an ECOG PS of 2. Among
23 patients aged ≥65 yr, 13 patients had an ECOG PS of
2. Thirteen patients were aged 70 yr or older. All patients
had measurable tumor lesions. Lung (68%), lymph nodes
(65%), pleura (63%), bone (40%), and adrenal glands (20%)
were the most common metastatic sites. 
Twenty-nine patients (73%) received weekly low-dose doc-
etaxel as second-line chemotherapy, eight patients (20%) as
third-line therapy and three patients (8%) as fourth-line treat-
ment. Most of the patients (≥90%) were previously treated
with gemcitabine plus platinum combination chemothera-
py as first-line therapy. Among 11 patients who received
weekly docetaxel as ≥third-line chemotherapy, nine patients
had been previously exposed to epidermal growth factor
Characteristics (N=40) Patient number
Table 1. Patient characteristics
No. of patients enrolled 40
Assessable for response 37 (93%)
Assessable for toxicity 40 (100%)
Age (Median 66 yr [Range: 33-80])
<65 yr:≥65 yr 17 (43%):23 (58%)
Gender (male:female) 24 (60%):16 (40%)
ECOG performance status (0-1:2) 10 (25%):30 (75%)
Stage (IIIB:IV) 4 (10%):36 (90%)
Pathology
Adenocarcinoma 22 (55%)
Squamous cell carcinoma 9 (23%)
Others 9 (23%)
Site of metastasis
Lung to lung  27 (68%)
Lymph node 26 (65%)
Pleura 25  (63%)
Bone 16  (40%)
Adrenal gland 8 (20%)
Pericardium 5 (13%)
Liver 4  (10%)
Brain 4  (10%)
Salvage chemotherapy
Second-line therapy:≥Third-line therapy 29:11
Prior chemotherapy
Weekly docetaxel as second-line therapy 
(N=29, 73%)
Platinum 28/29 (97%)
Gemcitabine 27/29 (93%)
Paclitaxel 3/29 (10%)
Weakly docetaxel as ≥ third-line 
chemotherapy (N=11, 28%)
Platinum 11/11 (100%)
Gemcitabine 10/11 (91%)
EGFR inhibitor 9/11 (82%)
Paclitaxel 6/11 (55%)
Vinorelbine 2/11 (17%)
Total patients (N=40)
Platinum 39/40 (98%)
Gemcitabine 37/40 (93%)
Paclitaxel 9/40 (23%)
EGFR inhibitor 9/40 (23%)
Vinorelbine 2/40 (5%)
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth
factor receptor.Weekly Docetaxel in Elderly or Poor PS Patients with NSCLC 995
receptor (EGFR) tyrosine kinase inhibitors. As a whole, plat-
inum, gemcitabine, paclitaxel, and EGFR inhibitors were
previously employed in 39 (98%), 37 (93%), 9 (23%), and
9 patients (23%), respectively. 
Drug delivery
Among the 40 patients who received chemotherapy, 3
patients (8%) dropped out early before the response evalua-
tion for the chemotherapy; two patients who had severe
fatigue rejected further treatment and one patient discon-
tinued the study treatment due to early death (respiratory
failure caused by severe pneumonia). 
There were 112 treatment cycles delivered, with a median
of 2 cycles per patient (range: 1-6). Five patients (13%) received
the planned 6 cycles of chemotherapy. The reasons for pre-
mature treatment cessation were disease progression (n=25),
toxicity (n=6), concurrent disease (n=1), or the patient’s deci-
sion to end treatment (n=3). The relative dose intensity (RDI)
was calculated according to the method described by Hryniuk
(15). The calculated mean dose intensity for docetaxel was
17.8 mg/m2/week and the RDI was 95%.
Objective tumor responses
Of the 40 patients who received chemotherapy, three pa-
tients (8%) could not be evaluated for a response. By the
intent-to-treat analysis, the overall response rate was 23%
(95% confidence interval [CI]: 12-38%); nine of the 40 pa-
tients achieved a PR. Eleven patients (28%) had SD, and 17
patients (43%) had tumor progression. The disease control
rate (CR+PR+SD) was thus 50%. Among the 13 patients
who were ≥70 yr (ECOG PS 0-2), 3 patients (23%) had a
PR. In addition, PR was observed in two patients (15%)
out of the 13 patients who were ≥65 yr and had an ECOG
PS of grade 2.
Among the 29 patients who received weekly docetaxel as
a second-line therapy, five patients achieved a PR. Four of
the 11 patients treated with weekly docetaxel as ≥third-line
treatment had a PR. Of the 28 patients who had experienced
clinical benefits (CR, PR or SD) from first-line chemothera-
py, 8 patients (29%) achieved a PR after salvage weekly doc-
etaxel chemotherapy. However, among the 12 patients who
had shown PD after first-line chemotherapy, only one patient
(8%) achieved a PR after salvage docetaxel treatment. 
Adverse events
Toxicities were evaluated in all 40 patients and the results
are summarized in Table 2. The most common hematologi-
cal toxicity was anemia (35%). Of the grade 3 or 4 hemato-
logical toxicities, there was only one case (3%) of grade 3
neutropenia. No patient experienced a febrile neutropenia
and no grade ≥3 anemia or thrombocytopenia was observed.
Grade 1 Grade 2 Grade 3 Grade 4
Table 2. Hematological and non-hematological toxicities
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Fig. 1. Kaplan-Meier survival curve for progression-free survival.
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Fig. 2. Kaplan-Meier survival curve for overall survival.
Hematologic toxicities
Anemia 13 (33%) 1 (3%) --
Leucopenia 3 (8%) 2 (5%) --
Neutropenia -- 1 (3%) -
Thrombocytopenia --- -
Neutropenic fever  --- -
Non-hematologic toxicities
Fatigue 10 (25%) 5 (13%) 3 (8%) -
Anorexia 8 (20%) 7 (18%) 3 (8%) -
Emesis 10 (25%) 4 (10%) --
Stomatitis 2 (5%) 4 (10%) 2 (5%) -
Diarrhea 5 (13%) - 1 (3%) -
Hepatic dysfuction 2 (5%) -- -
Renal dysfunction 2 (5%) -- -
Peripheral neuropathy 3 (8%) - 1 (3%) -996 K.-W. Lee, J.H. Lim, J.H. Kim, et al.
Non-hematological toxicities consisted mainly of fatigue,
anorexia, emesis, and stomatitis. Both fatigue and anorexia
occurred in 18 patients (45%). However, severe fatigue or
anorexia (grade ≥3) developed in three patients (8%). Nau-
sea and vomiting occurred in 14 patients (35%) and no
patient experienced severe emesis. Eight patients (20%)
developed stomatitis, but only two (5%) patients suffered
from severe stomatitis (grade ≥3). No patient experienced
infusion-related hypersensitivity during the chemotherapy. 
Six patients (15%) could not complete the planned sched-
ule of chemotherapy because of related toxicities. Among
these six patients, three patients could not be evaluated for
response to chemotherapy. Three patients rejected receiving
further treatment due to severe fatigue, and one patient could
not receive further chemotherapy due to severe anorexia.
One patient had a pulmonary thromboembolism during
the chemotherapy and the docetaxel treatment was with-
drawn. One patient discontinued the study treatment due
to an early death (respiratory failure caused by severe pneu-
monia). Among the 13 patients who were ≥70 yr (ECOG
PS 0-2), three patients (23%) could not complete the planned
chemotherapy due to the adverse effects of the treatment.
Out of the 13 patients who were ≥65 yr and had an ECOG
PS of grade 2, the weekly docetaxel therapy was also perma-
nently stopped in three patients (23%) because of chemother-
apy-related toxicities. 
Survival
The median follow-up duration of all patients was 25.9
weeks (range: 2.7-61.6 weeks) and the median follow-up
duration of survivors was 35.3 weeks (range: 20.3-61.6
weeks). The median PFS of all patients (N=40) after the
initiation of the weekly docetaxel chemotherapy was 9.9
weeks (95% CI, 7.0-12.8 weeks, Fig. 1). The median PFS
of responders (N=9) was 24.4 weeks (95% CI, 22.0-26.8
weeks) and the median PFS of patients with SD (N=11)
was 15.1 weeks (95% CI, 9.5-20.7 weeks), respectively. The
median OS of all patents was 37.7 weeks (95% CI, 20.0-
55.4 weeks, Fig. 2). 
DISCUSSION
The results of our study support the safety and efficacy of
weekly low-dose docetaxel (25 mg/m2) for the treatment of
elderly NSCLC patients (≥65 yr) or patients of any age with
poor PS who were previously treated with chemotherapy.
The overall response rate was 23% with a median PFS and
OS of 9.9 and 37.7 weeks, respectively. Compared with con-
ventional 3-weekly or weekly higher-dose docetaxel regi-
mens (10-13, 16-19), this weekly low-dose regimen showed
similar efficacy as salvage therapy in NSCLC patients. More-
over, despite the fragility of the enrolled patients, the observed
toxicities were generally well tolerated. 
Hainsworth et al. reported that the maximum tolerated
dose (MTD) of weekly docetaxel was 43 mg/m2/week in
patients with advanced refractory tumors (20). Several clini-
cal trials, using weekly docetaxel monotherapy, have been
performed for NSCLC. However, these prior studies had dif-
ferent docetaxel doses (range, 25 to 40 mg/m2) and in addi-
tion, the sequence of weeks with and without treatment dif-
fered (10-13, 16-19, 21-24). Three randomized phase III
trials that compared docetaxel administered weekly with
every 3 weeks, in previously treated NSCLC patients, demon-
strated that weekly docetaxel regimens had a similar response
and survival rates and superior hematological toxicity pro-
files compared to the 3-weekly schedule (10-12). Based on
the better toxicity profiles and no relevant difference in sur-
vival, weekly docetaxel chemotherapy appears to be a valid
alternative to the conventional 3-week cycle for treatment
of NSCLC patients as second-line chemotherapy (13). The
weekly regimen may provide an attractive treatment option
for elderly patients or those with poor PS who are usually
not candidates for the full-dose 3-week docetaxel regimen.
The data available for weekly docetaxel chemotherapy tar-
geting elderly patients or patients with poor PS is limited.
A Minnie Pearl Cancer Research Network phase II trial per-
formed in the elderly (≥65 yr old) or younger patients who
were considered poor candidates for combination chemother-
apy for NSCLC used a weekly docetaxel dose of 36 mg/m2
for 6 weeks as first-line treatment. An 18% response rate
and moderate toxicities were reported (21). A French multi-
center phase II study performed in elderly NSCLC patients
(≥70 yr old), with a schedule of 30 mg/m2 for 6 consecu-
tive weeks, followed by a 2-week treatment-free period as
first-line therapy, showed acceptable toxicities and moderate
activity (response rate 10%; median PFS and OS of 2.2 and
4.3 months, respectively) (22). In a phase II study performed
in elderly (≥70 yr) or PS 2 patients with NSCLC in the Unit-
ed States, using docetaxel 30 mg/m2 on days 1, 8, and 15
every 4 weeks as first-line treatment, the response rate was
5.4% and the median PFS and OS were 2.3 and 6.7 months,
respectively (23). 
However, the adequate dosage for weekly docetaxel thera-
py in the elderly or poor PS patients is controversial. In one
pharmacokinetic and toxicity study in Western elderly pa-
tients (≥65 yr old), weekly docetaxel administered at 35
mg/m2 for 3 weeks followed by a 1-week break caused a
grade ≥3 toxicity in over half of the patients. As a result of
these findings, the investigators recommended a starting
dose of 26 mg/m2 for this weekly schedule and dose escala-
tion with no toxicity (25). Asian elderly patients appear to
have lower tolerance for weekly docetaxel than Western
patients do. In a phase I trial performed in Japanese patients
(≥70 yr old), docetaxel was administered on days 1, 8, and
15 for each 28-day cycle. The MTD was 30 mg/m2/week
and a dose of 25 mg/m2/week was recommended for futureWeekly Docetaxel in Elderly or Poor PS Patients with NSCLC 997
clinical trials (26).
Our study is the first reported trial of weekly docetaxel
therapy in previously treated elderly patients or PS 2 patients
with advanced NSCLC as salvage treatment. Ninety-eight
percent of patients were previously exposed to platinum-
based chemotherapy and 28% of patients received weekly
docetaxel therapy as ≥third-line treatment. Although pa-
tients included in this study were fragile patients, therapeu-
tic outcomes of the weekly low-dose docetaxel in these pa-
tients were in line with those of other trials, where younger
or fitter patients were enrolled and/or higher weekly doses
of docetaxel were used (10-12, 16-19). However, our study
has some limitations. First, the elderly and PS 2 patients
may have different characteristics; it has become increasing-
ly evident that trials evaluating treatments for patients with
poor PS should be conducted separately from those evaluat-
ing elderly patients (23, 26). At the time when this study
was conceived, both subsets were considered special popula-
tions, primarily due to a lack of evidence-based data from
large randomized trials, and thus elderly patients with good
PS and patients of any age with poor PS were enrolled simul-
taneously (21, 23). Second, elderly patients were included
in this study on the basis of chronological age alone without
the consideration of geriatric criteria taking into account the
general condition of the patients, comorbidity, cognitive, or
functional status. Recent reports suggest that the frailty of
elderly patients for receiving chemotherapy should not be
judged by age alone and selected fit-elderly patients can tol-
erate conventional chemotherapy as young patients (27).
Despite these limitations, the results of our study confirm
the safety and efficacy of weekly low-dose docetaxel in these
patients. 
In conclusion, weekly low-dose docetaxel monotherapy
was well-tolerated as salvage chemotherapy for previously
treated elderly or poor PS patients with NSCLC. This app-
roach provides a reasonable alternative for pretreated elderly
or less fit patients with NSCLC.
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